Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fevipiprant chewable tablet PK, safety and tolerability in children with asthma (6 to <12 years)
2018-003920-35Phase 2Terminated
- Sponsor
- Novartis
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fevipiprant in asthma, sponsored by Novartis. Primary endpoints: Area under the curve at steady state (AUC0-24h,ss), Maximum plasma concentration at steady state (Cmax,ss) and 1 more. Started Apr 2019; status: terminated.
02
Drugs
fevipiprant
03
Conditions
asthma
Beyond the preview
Go deeper on 2018-003920-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003920-35.